Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow turns positive

Q1 FY2026 investing cash flow was $34K, compared with -$137K a year earlier. Trailing-twelve-month investing cash flow was -$59.66K. Over 3 fiscal years it compounded at -69.0% a year.

Context

  • Investing cash flow amounted to 0.3% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Investing cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near $34K or moves back toward the trailing-twelve-month quarterly average of -$14.92K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$34K-61.1% QoQ
Last fiscal yearDec 2025
-$230K-64.5% YoY
LTMMar 2026
-$59.66K-89.1% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+124.8%——
1 year-64.5%——
3-year CAGR-69.0%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(230K) USD
Year-over-year change
+64.5%

Investing Cash Flow vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -89.1% is the 9th highest of 10, against a peer median of -67.3%.
  • Investing cash flow amounts to 0.1% of revenue for ARCT, versus a peer median of 6.3%.
ARCT Competitors
Investing Cash Flow for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$195.39M USD-67.3%—298.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$179.25M USD+363.9%——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$132.92M USD+56.5%——
NVAXNovavax, Inc.LTM Mar 2026$33.31M USD-87.7%-5.6%5.6%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$16.73M USD-71.5%-49.6%—
ABUSArbutus Biopharma CorporationLTM Mar 2026$6.43M USD-71.6%—3.4%
SLNSilence Therapeutics plcLTM Mar 2026$6.39M USD—+32.8%693.3%
VALNValneva SELTM Mar 2026€5.77M EUR-46.4%-61.1%3.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026€955.79K EUR-107.1%+11.8%7.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$59.66K USD-89.1%-69.0%0.1%
BNTCBenitec Biopharma Inc.LTM Mar 2026$27.51K USD+48.2%+11.5%—
Peer median (excluding ARCT) —-67.3%+2.9%6.3%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.